NGS-Based Monitoring and Diagnostic Test is based on the NGS, aiming for the monitoring and diagnostic test. Next generation sequencing (NGS), massively parallel or deep sequencing are related terms that describe a DNA sequencing technology which has revolutionised genomic research. Using NGS an entire human genome can be sequenced within a single day.
The global market for NGS-Based Monitoring and Diagnostic Test was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for NGS-Based Monitoring and Diagnostic Test, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of NGS-Based Monitoring and Diagnostic Test by region & country, by Type, and by Application.
The NGS-Based Monitoring and Diagnostic Test market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding NGS-Based Monitoring and Diagnostic Test.
麻豆原创 Segmentation
By Company
Agilent Technologies, Inc.
Ancestry LLC
ArcherDX, Inc.
Beijing Genomics Institute (BGI)
Cancer Genetics, Inc.
CENTOGENE AG
F. Hoffmann-La Roche Ltd
GenePath Dx
Illumina, Inc.
Laboratory Corporation of America Holdings
Myriad Genetics, Inc.
QIAGEN N.V.
Quest Diagnostics Incorporated
Siemens Healthineers, Inc.
Thermo Fisher Scientific Inc.
HTG Molecular Diagnostics, Inc.
Vela Diagnostics Pte. Ltd.
Segment by Type:
Commercial Assays/Tests
Laboratory Developed Tests
Direct to Consumer Test
Pre-Commercial Tests
Segment by Application
Out-Patient Clinics/General Practitioners
Diagnostic Centers
Hospitals
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of NGS-Based Monitoring and Diagnostic Test manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of NGS-Based Monitoring and Diagnostic Test in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of NGS-Based Monitoring and Diagnostic Test in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 麻豆原创 Overview
1.1 NGS-Based Monitoring and Diagnostic Test Product Introduction
1.2 Global NGS-Based Monitoring and Diagnostic Test 麻豆原创 Size Forecast
1.3 NGS-Based Monitoring and Diagnostic Test 麻豆原创 Trends & Drivers
1.3.1 NGS-Based Monitoring and Diagnostic Test Industry Trends
1.3.2 NGS-Based Monitoring and Diagnostic Test 麻豆原创 Drivers & Opportunity
1.3.3 NGS-Based Monitoring and Diagnostic Test 麻豆原创 Challenges
1.3.4 NGS-Based Monitoring and Diagnostic Test 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global NGS-Based Monitoring and Diagnostic Test Players Revenue Ranking (2023)
2.2 Global NGS-Based Monitoring and Diagnostic Test Revenue by Company (2019-2024)
2.3 Key Companies NGS-Based Monitoring and Diagnostic Test Manufacturing Base Distribution and Headquarters
2.4 Key Companies NGS-Based Monitoring and Diagnostic Test Product Offered
2.5 Key Companies Time to Begin Mass Production of NGS-Based Monitoring and Diagnostic Test
2.6 NGS-Based Monitoring and Diagnostic Test 麻豆原创 Competitive Analysis
2.6.1 NGS-Based Monitoring and Diagnostic Test 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by NGS-Based Monitoring and Diagnostic Test Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in NGS-Based Monitoring and Diagnostic Test as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Commercial Assays/Tests
3.1.2 Laboratory Developed Tests
3.1.3 Direct to Consumer Test
3.1.4 Pre-Commercial Tests
3.2 Global NGS-Based Monitoring and Diagnostic Test Sales Value by Type
3.2.1 Global NGS-Based Monitoring and Diagnostic Test Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global NGS-Based Monitoring and Diagnostic Test Sales Value, by Type (2019-2030)
3.2.3 Global NGS-Based Monitoring and Diagnostic Test Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Out-Patient Clinics/General Practitioners
4.1.2 Diagnostic Centers
4.1.3 Hospitals
4.1.4 Others
4.2 Global NGS-Based Monitoring and Diagnostic Test Sales Value by Application
4.2.1 Global NGS-Based Monitoring and Diagnostic Test Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global NGS-Based Monitoring and Diagnostic Test Sales Value, by Application (2019-2030)
4.2.3 Global NGS-Based Monitoring and Diagnostic Test Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global NGS-Based Monitoring and Diagnostic Test Sales Value by Region
5.1.1 Global NGS-Based Monitoring and Diagnostic Test Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global NGS-Based Monitoring and Diagnostic Test Sales Value by Region (2019-2024)
5.1.3 Global NGS-Based Monitoring and Diagnostic Test Sales Value by Region (2025-2030)
5.1.4 Global NGS-Based Monitoring and Diagnostic Test Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America NGS-Based Monitoring and Diagnostic Test Sales Value, 2019-2030
5.2.2 North America NGS-Based Monitoring and Diagnostic Test Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe NGS-Based Monitoring and Diagnostic Test Sales Value, 2019-2030
5.3.2 Europe NGS-Based Monitoring and Diagnostic Test Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific NGS-Based Monitoring and Diagnostic Test Sales Value, 2019-2030
5.4.2 Asia Pacific NGS-Based Monitoring and Diagnostic Test Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America NGS-Based Monitoring and Diagnostic Test Sales Value, 2019-2030
5.5.2 South America NGS-Based Monitoring and Diagnostic Test Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa NGS-Based Monitoring and Diagnostic Test Sales Value, 2019-2030
5.6.2 Middle East & Africa NGS-Based Monitoring and Diagnostic Test Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions NGS-Based Monitoring and Diagnostic Test Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions NGS-Based Monitoring and Diagnostic Test Sales Value
6.3 United States
6.3.1 United States NGS-Based Monitoring and Diagnostic Test Sales Value, 2019-2030
6.3.2 United States NGS-Based Monitoring and Diagnostic Test Sales Value by Type (%), 2023 VS 2030
6.3.3 United States NGS-Based Monitoring and Diagnostic Test Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe NGS-Based Monitoring and Diagnostic Test Sales Value, 2019-2030
6.4.2 Europe NGS-Based Monitoring and Diagnostic Test Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe NGS-Based Monitoring and Diagnostic Test Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China NGS-Based Monitoring and Diagnostic Test Sales Value, 2019-2030
6.5.2 China NGS-Based Monitoring and Diagnostic Test Sales Value by Type (%), 2023 VS 2030
6.5.3 China NGS-Based Monitoring and Diagnostic Test Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan NGS-Based Monitoring and Diagnostic Test Sales Value, 2019-2030
6.6.2 Japan NGS-Based Monitoring and Diagnostic Test Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan NGS-Based Monitoring and Diagnostic Test Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea NGS-Based Monitoring and Diagnostic Test Sales Value, 2019-2030
6.7.2 South Korea NGS-Based Monitoring and Diagnostic Test Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea NGS-Based Monitoring and Diagnostic Test Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia NGS-Based Monitoring and Diagnostic Test Sales Value, 2019-2030
6.8.2 Southeast Asia NGS-Based Monitoring and Diagnostic Test Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia NGS-Based Monitoring and Diagnostic Test Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India NGS-Based Monitoring and Diagnostic Test Sales Value, 2019-2030
6.9.2 India NGS-Based Monitoring and Diagnostic Test Sales Value by Type (%), 2023 VS 2030
6.9.3 India NGS-Based Monitoring and Diagnostic Test Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Agilent Technologies, Inc.
7.1.1 Agilent Technologies, Inc. Profile
7.1.2 Agilent Technologies, Inc. Main Business
7.1.3 Agilent Technologies, Inc. NGS-Based Monitoring and Diagnostic Test Products, Services and Solutions
7.1.4 Agilent Technologies, Inc. NGS-Based Monitoring and Diagnostic Test Revenue (US$ Million) & (2019-2024)
7.1.5 Agilent Technologies, Inc. Recent Developments
7.2 Ancestry LLC
7.2.1 Ancestry LLC Profile
7.2.2 Ancestry LLC Main Business
7.2.3 Ancestry LLC NGS-Based Monitoring and Diagnostic Test Products, Services and Solutions
7.2.4 Ancestry LLC NGS-Based Monitoring and Diagnostic Test Revenue (US$ Million) & (2019-2024)
7.2.5 Ancestry LLC Recent Developments
7.3 ArcherDX, Inc.
7.3.1 ArcherDX, Inc. Profile
7.3.2 ArcherDX, Inc. Main Business
7.3.3 ArcherDX, Inc. NGS-Based Monitoring and Diagnostic Test Products, Services and Solutions
7.3.4 ArcherDX, Inc. NGS-Based Monitoring and Diagnostic Test Revenue (US$ Million) & (2019-2024)
7.3.5 Beijing Genomics Institute (BGI) Recent Developments
7.4 Beijing Genomics Institute (BGI)
7.4.1 Beijing Genomics Institute (BGI) Profile
7.4.2 Beijing Genomics Institute (BGI) Main Business
7.4.3 Beijing Genomics Institute (BGI) NGS-Based Monitoring and Diagnostic Test Products, Services and Solutions
7.4.4 Beijing Genomics Institute (BGI) NGS-Based Monitoring and Diagnostic Test Revenue (US$ Million) & (2019-2024)
7.4.5 Beijing Genomics Institute (BGI) Recent Developments
7.5 Cancer Genetics, Inc.
7.5.1 Cancer Genetics, Inc. Profile
7.5.2 Cancer Genetics, Inc. Main Business
7.5.3 Cancer Genetics, Inc. NGS-Based Monitoring and Diagnostic Test Products, Services and Solutions
7.5.4 Cancer Genetics, Inc. NGS-Based Monitoring and Diagnostic Test Revenue (US$ Million) & (2019-2024)
7.5.5 Cancer Genetics, Inc. Recent Developments
7.6 CENTOGENE AG
7.6.1 CENTOGENE AG Profile
7.6.2 CENTOGENE AG Main Business
7.6.3 CENTOGENE AG NGS-Based Monitoring and Diagnostic Test Products, Services and Solutions
7.6.4 CENTOGENE AG NGS-Based Monitoring and Diagnostic Test Revenue (US$ Million) & (2019-2024)
7.6.5 CENTOGENE AG Recent Developments
7.7 F. Hoffmann-La Roche Ltd
7.7.1 F. Hoffmann-La Roche Ltd Profile
7.7.2 F. Hoffmann-La Roche Ltd Main Business
7.7.3 F. Hoffmann-La Roche Ltd NGS-Based Monitoring and Diagnostic Test Products, Services and Solutions
7.7.4 F. Hoffmann-La Roche Ltd NGS-Based Monitoring and Diagnostic Test Revenue (US$ Million) & (2019-2024)
7.7.5 F. Hoffmann-La Roche Ltd Recent Developments
7.8 GenePath Dx
7.8.1 GenePath Dx Profile
7.8.2 GenePath Dx Main Business
7.8.3 GenePath Dx NGS-Based Monitoring and Diagnostic Test Products, Services and Solutions
7.8.4 GenePath Dx NGS-Based Monitoring and Diagnostic Test Revenue (US$ Million) & (2019-2024)
7.8.5 GenePath Dx Recent Developments
7.9 Illumina, Inc.
7.9.1 Illumina, Inc. Profile
7.9.2 Illumina, Inc. Main Business
7.9.3 Illumina, Inc. NGS-Based Monitoring and Diagnostic Test Products, Services and Solutions
7.9.4 Illumina, Inc. NGS-Based Monitoring and Diagnostic Test Revenue (US$ Million) & (2019-2024)
7.9.5 Illumina, Inc. Recent Developments
7.10 Laboratory Corporation of America Holdings
7.10.1 Laboratory Corporation of America Holdings Profile
7.10.2 Laboratory Corporation of America Holdings Main Business
7.10.3 Laboratory Corporation of America Holdings NGS-Based Monitoring and Diagnostic Test Products, Services and Solutions
7.10.4 Laboratory Corporation of America Holdings NGS-Based Monitoring and Diagnostic Test Revenue (US$ Million) & (2019-2024)
7.10.5 Laboratory Corporation of America Holdings Recent Developments
7.11 Myriad Genetics, Inc.
7.11.1 Myriad Genetics, Inc. Profile
7.11.2 Myriad Genetics, Inc. Main Business
7.11.3 Myriad Genetics, Inc. NGS-Based Monitoring and Diagnostic Test Products, Services and Solutions
7.11.4 Myriad Genetics, Inc. NGS-Based Monitoring and Diagnostic Test Revenue (US$ Million) & (2019-2024)
7.11.5 Myriad Genetics, Inc. Recent Developments
7.12 QIAGEN N.V.
7.12.1 QIAGEN N.V. Profile
7.12.2 QIAGEN N.V. Main Business
7.12.3 QIAGEN N.V. NGS-Based Monitoring and Diagnostic Test Products, Services and Solutions
7.12.4 QIAGEN N.V. NGS-Based Monitoring and Diagnostic Test Revenue (US$ Million) & (2019-2024)
7.12.5 QIAGEN N.V. Recent Developments
7.13 Quest Diagnostics Incorporated
7.13.1 Quest Diagnostics Incorporated Profile
7.13.2 Quest Diagnostics Incorporated Main Business
7.13.3 Quest Diagnostics Incorporated NGS-Based Monitoring and Diagnostic Test Products, Services and Solutions
7.13.4 Quest Diagnostics Incorporated NGS-Based Monitoring and Diagnostic Test Revenue (US$ Million) & (2019-2024)
7.13.5 Quest Diagnostics Incorporated Recent Developments
7.14 Siemens Healthineers, Inc.
7.14.1 Siemens Healthineers, Inc. Profile
7.14.2 Siemens Healthineers, Inc. Main Business
7.14.3 Siemens Healthineers, Inc. NGS-Based Monitoring and Diagnostic Test Products, Services and Solutions
7.14.4 Siemens Healthineers, Inc. NGS-Based Monitoring and Diagnostic Test Revenue (US$ Million) & (2019-2024)
7.14.5 Siemens Healthineers, Inc. Recent Developments
7.15 Thermo Fisher Scientific Inc.
7.15.1 Thermo Fisher Scientific Inc. Profile
7.15.2 Thermo Fisher Scientific Inc. Main Business
7.15.3 Thermo Fisher Scientific Inc. NGS-Based Monitoring and Diagnostic Test Products, Services and Solutions
7.15.4 Thermo Fisher Scientific Inc. NGS-Based Monitoring and Diagnostic Test Revenue (US$ Million) & (2019-2024)
7.15.5 Thermo Fisher Scientific Inc. Recent Developments
7.16 HTG Molecular Diagnostics, Inc.
7.16.1 HTG Molecular Diagnostics, Inc. Profile
7.16.2 HTG Molecular Diagnostics, Inc. Main Business
7.16.3 HTG Molecular Diagnostics, Inc. NGS-Based Monitoring and Diagnostic Test Products, Services and Solutions
7.16.4 HTG Molecular Diagnostics, Inc. NGS-Based Monitoring and Diagnostic Test Revenue (US$ Million) & (2019-2024)
7.16.5 HTG Molecular Diagnostics, Inc. Recent Developments
7.17 Vela Diagnostics Pte. Ltd.
7.17.1 Vela Diagnostics Pte. Ltd. Profile
7.17.2 Vela Diagnostics Pte. Ltd. Main Business
7.17.3 Vela Diagnostics Pte. Ltd. NGS-Based Monitoring and Diagnostic Test Products, Services and Solutions
7.17.4 Vela Diagnostics Pte. Ltd. NGS-Based Monitoring and Diagnostic Test Revenue (US$ Million) & (2019-2024)
7.17.5 Vela Diagnostics Pte. Ltd. Recent Developments
8 Industry Chain Analysis
8.1 NGS-Based Monitoring and Diagnostic Test Industrial Chain
8.2 NGS-Based Monitoring and Diagnostic Test Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 NGS-Based Monitoring and Diagnostic Test Sales Model
8.5.2 Sales Channel
8.5.3 NGS-Based Monitoring and Diagnostic Test Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
Agilent Technologies, Inc.
Ancestry LLC
ArcherDX, Inc.
Beijing Genomics Institute (BGI)
Cancer Genetics, Inc.
CENTOGENE AG
F. Hoffmann-La Roche Ltd
GenePath Dx
Illumina, Inc.
Laboratory Corporation of America Holdings
Myriad Genetics, Inc.
QIAGEN N.V.
Quest Diagnostics Incorporated
Siemens Healthineers, Inc.
Thermo Fisher Scientific Inc.
HTG Molecular Diagnostics, Inc.
Vela Diagnostics Pte. Ltd.
听
听
*If Applicable.
